Skip to content

Study · Randomized controlled trial · n = 100 · 2018

3 results

No side-effects of single intranasal oxytocin administration in middle childhood.

Verhees MWFT, Houben J, Ceulemans E, Bakermans-Kranenburg MJ, van IJzendoorn MH, Bosmans G

Psychopharmacology18 Jun 2018Cited by 16 (Europe PMC)

PMID29915962 (opens in a new tab)DOI10.1007/s00213-018-4945-1 (opens in a new tab)PepBankPUB-29915962
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In children aged 8-12 years, single intranasal oxytocin did not significantly change the total frequency of reported side-effects versus placebo.

    In plain wordsIn children aged 8-12, one dose of oxytocin nasal spray did not cause more side-effects overall than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeTotal frequency of reported side-effects
    Study

    n = 100

    Comparator
    Placebo nasal spray
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intranasal · single administrationAs given in this study (human).

    Source sentences

    Summary
    There were no significant associations between nasal spray condition and total frequency of reported side-effects or reports of specific side-effects.
    1 context sentence
    Summary · context
    One hundred children (8-12 years old) were randomly assigned to receive oxytocin or placebo nasal spray.
  2. 02HumanRandomized controlled trialSafety outcome

    In children aged 8-12 years, single intranasal oxytocin was not significantly associated with reports of specific side-effects versus placebo.

    In plain wordsIn children aged 8-12, one dose of oxytocin nasal spray did not cause more of any specific side-effect than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeSpecific side-effects
    Study

    n = 100

    Comparator
    Placebo nasal spray
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intranasal · single administrationAs given in this study (human).

    Source sentences

    Summary
    There were no significant associations between nasal spray condition and total frequency of reported side-effects or reports of specific side-effects.
    1 context sentence
    Summary · context
    One hundred children (8-12 years old) were randomly assigned to receive oxytocin or placebo nasal spray.
  3. 03HumanRandomized controlled trialSafety outcome

    In children aged 8-12 years given intranasal oxytocin or placebo, most reported side-effects were mild and ceased within 24 hours.

    In plain wordsIn children aged 8-12, most side-effects reported after the nasal spray were mild and stopped within 24 hours.

    Peptide
    Oxytocin
    Outcome
    Not applicableSeverity and duration of side-effects
    Study

    n = 100

    Comparator
    Placebo nasal spray
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intranasal · single administrationAs given in this study (human).

    Source sentences

    Summary
    the majority of reported side-effects were classified as mild and ceased within 24 h after the procedure
    1 context sentence
    Summary · context
    One hundred children (8-12 years old) were randomly assigned to receive oxytocin or placebo nasal spray.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.